Effects of 5-methoxytryptophan on cardiac structure and functions in a rat model of diabetic cardiomyopathy

Table 2 Changes in cardiac systolic function after 8 days, 16 days, and 32 days of 5-methoxytryptophan treatment in a rat model of diabetic cardiomyopathy

Treatment group	Day 8	P value	Day 16	P value	Day 32	P value
ΔLVEF
DCM (control)	-13.83 ± 3.87		-1.07 ± 8.51		2.43 ± 8.17
DCM + 5-MTP 25 mg/kg	-2.12 ± 5.20	0.135	6.94 ± 7.38	0.212	-3.07 ± 14.37	0.511
DCM + 5-MTP 50 mg/kg	-5.40 ± 17.47	0.271	5.95 ± 6.39	0.271	-3.10 ± 13.91	0.509
DCM + 5-MTP 100 mg/kg	1.32 ± 8.86	0.060	3.71 ± 11.29	0.447	-6.44 ± 7.80	0.296
P for treatment vs control		0.245		0.576		0.749
ΔFS
DCM (control)	-14.18 ± 7.05		-0.73 ± 6.90		3.61 ± 8.73
DCM + 5-MTP 25 mg/kg	-2.72 ± 4.99	0.106	6.56 ± 7.28	0.259	-1.06 ± 9.51	0.543
DCM + 5-MTP 50 mg/kg	-4.24 ± 14.01	0.155	5.93 ± 6.20	0.300	-0.94 ± 13.73	0.553
DCM + 5-MTP 100 mg/kg	1.67 ± 8.50	0.032a	5.69 ± 12.78	0.317	-6.97 ± 9.45	0.181
P for treatment vs control		0.155		0.617		0.583

^aP < 0.05.

Normally distributed data are presented as mean ± SD and analyzed using one-way analysis of variance; non-normally distributed numerical data are presented as median (minimum-maximum) and analyzed using the Kruskal-Wallis test. Comparisons between the control group and treatment groups were performed using post hoc least significant difference for normally distributed data and pairwise Bonferroni testing for non-normally distributed data. 5-MTP: 5-Methoxytryptophan; DCM: Diabetic cardiomyopathy; LVEF: Left ventricular ejection fraction; FS: Fractional shortening.